Due to very low enrollment rate the study was terminated.

CORAMI trial is a prospective, international, multicenter randomized study which will be performed in experienced invasive facility centres with 24/7 PCI (percutaneous coronary intervention) duty and patient enrollment will continue for 18 months (October 2010 - March 2012).The aim of the study is to compare strategy of complete vs target lesion-only primary PCI in IRA (infarct related artery) in STEMI (ST elevation myocardial infarction) patients.

Inclusion Criteria:

• diagnosis of STEMI (according to ESC 2007 definition)
• Chest pain onset <12 hours
• signed informed consent
• Presence of two critical lesions requiring PCI in IRA (LAD - left anterior descending, Cx - circumflex, RCA - right coronary artery)
• Target/culprit lesion which requires immediate stenting (>50 - 100%) and second critical lesion (70-90%) with TIMI 3 flow after PCI of the 1st target/culprit lesion
• Over 18 years of age
• IRA diameter ≥ 2.5 mm

Exclusion Criteria:

• Terminal illness with life expectancy less <1 year or active cancer disease - Pregnancy or possibility of pregnancy
• Second critical lesion in IRA >90% or occlusion
• Contraindications to PCI or/and stent implantation
• Contraindications to DES stent implantation
• Lesion diameters unsuitable for intended stent platform
• Active bleeding or coagulopathy
• Patient in cardiogenic shock (<90mmHg SBP and/or requiring IABP - intraaortic balloon pump - or vasopressors) - Killip 4 class
• Patient has Left Bundle Branch Block (LBBB) or pacemaker rhythm
• No future patient cooperation expected
• Patient is participating in another clinical study